Market Cap 4.09M
Revenue (ttm) 7.19M
Net Income (ttm) -50.08M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -696.52%
Debt to Equity Ratio 0.00
Volume 4,010,500
Avg Vol 1,494,488
Day's Range N/A - N/A
Shares Out 21.04M
Stochastic %K 5%
Beta 0.35
Analysts Hold
Price Target $5.00

Company Profile

T2 Biosystems, Inc. engages in the development and commercialization of medical diagnostic products for critical unmet needs in the healthcare. Its products include T2Dx instrument, T2Candida panel, and T2Bacteria panel. The company was incorporated in 2006 and is based in Lexington, Massachusetts.

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 781 761 4646
Address:
101 Hartwell Avenue, Lexington, United States
Vincent_2026
Vincent_2026 Apr. 2 at 2:06 AM
$TTOO Cardinal Health is the "incumbent" partner that has the most to lose—or gain—from the final disposition of T2 Biosystems' assets. As of today, April 1, 2026, here is the status of the relationship and how Cardinal fits into the current auction landscape. Cardinal has a vested interest in ensuring that whoever buys the IP continues to support the hardware already in the field, as Cardinal has already invested significant sales resources into placing these units. Interestingly, CAH is also showing extreme financial strength right now and aggressively expanding its BioPharma Solutions and Specialty Distribution arms. If they feel a competitor like Danaher might "choke off" their access to T2's diagnostic panels, Cardinal has the capital to bid on the assets themselves to bring the manufacturing in-house. Watch the "Assigned Contracts": When the 8-K filing drops (expected between April 6–7), look for "Cardinal Health Distribution Agreement" listing as an Assumed Contract.
1 · Reply
bjay11
bjay11 Apr. 2 at 1:32 AM
$TTOO We're not alone
1 · Reply
LicketySplitz03
LicketySplitz03 Apr. 1 at 9:45 PM
$TTOO https://newsroom.cardinalhealth.com/2026-03-31-Cardinal-Health-recognized-by-industry-peers-for-leadership-in-supplier-transparency-and-resiliency
0 · Reply
Vincent_2026
Vincent_2026 Apr. 1 at 6:54 PM
$TTOO data on OTC Expert today seems to be not available?
1 · Reply
StockDreamin
StockDreamin Apr. 1 at 3:38 PM
$TTOO crapola! No life saving machines!
0 · Reply
Vincent_2026
Vincent_2026 Apr. 1 at 3:11 PM
$TTOO zero volume this morning
0 · Reply
bjay11
bjay11 Apr. 1 at 3:07 PM
$TTOO Looks as though trading has ceased. Now we wait.
3 · Reply
The_eye_of_the_tiger
The_eye_of_the_tiger Apr. 1 at 8:34 AM
1 · Reply
bjay11
bjay11 Apr. 1 at 8:07 AM
$TTOO Wow !!!!!! $375000 deposited in my cash account !!! Check your accounts peeps
2 · Reply
LicketySplitz03
LicketySplitz03 Apr. 1 at 12:41 AM
$TTOO https://www.linkedin.com/posts/sepsis-qualityimprovement-healthcareleadership-share-7444821614246043649-xyDH?utm_source=social_share_send&utm_medium=ios_app&rcm=ACoAAEYxpb4Bm1Ed1IOOY8fbukunVJhWnTe2X9I&utm_campaign=share_via
0 · Reply
Latest News on TTOO
No data available.
Vincent_2026
Vincent_2026 Apr. 2 at 2:06 AM
$TTOO Cardinal Health is the "incumbent" partner that has the most to lose—or gain—from the final disposition of T2 Biosystems' assets. As of today, April 1, 2026, here is the status of the relationship and how Cardinal fits into the current auction landscape. Cardinal has a vested interest in ensuring that whoever buys the IP continues to support the hardware already in the field, as Cardinal has already invested significant sales resources into placing these units. Interestingly, CAH is also showing extreme financial strength right now and aggressively expanding its BioPharma Solutions and Specialty Distribution arms. If they feel a competitor like Danaher might "choke off" their access to T2's diagnostic panels, Cardinal has the capital to bid on the assets themselves to bring the manufacturing in-house. Watch the "Assigned Contracts": When the 8-K filing drops (expected between April 6–7), look for "Cardinal Health Distribution Agreement" listing as an Assumed Contract.
1 · Reply
bjay11
bjay11 Apr. 2 at 1:32 AM
$TTOO We're not alone
1 · Reply
LicketySplitz03
LicketySplitz03 Apr. 1 at 9:45 PM
$TTOO https://newsroom.cardinalhealth.com/2026-03-31-Cardinal-Health-recognized-by-industry-peers-for-leadership-in-supplier-transparency-and-resiliency
0 · Reply
Vincent_2026
Vincent_2026 Apr. 1 at 6:54 PM
$TTOO data on OTC Expert today seems to be not available?
1 · Reply
StockDreamin
StockDreamin Apr. 1 at 3:38 PM
$TTOO crapola! No life saving machines!
0 · Reply
Vincent_2026
Vincent_2026 Apr. 1 at 3:11 PM
$TTOO zero volume this morning
0 · Reply
bjay11
bjay11 Apr. 1 at 3:07 PM
$TTOO Looks as though trading has ceased. Now we wait.
3 · Reply
The_eye_of_the_tiger
The_eye_of_the_tiger Apr. 1 at 8:34 AM
1 · Reply
bjay11
bjay11 Apr. 1 at 8:07 AM
$TTOO Wow !!!!!! $375000 deposited in my cash account !!! Check your accounts peeps
2 · Reply
LicketySplitz03
LicketySplitz03 Apr. 1 at 12:41 AM
$TTOO https://www.linkedin.com/posts/sepsis-qualityimprovement-healthcareleadership-share-7444821614246043649-xyDH?utm_source=social_share_send&utm_medium=ios_app&rcm=ACoAAEYxpb4Bm1Ed1IOOY8fbukunVJhWnTe2X9I&utm_campaign=share_via
0 · Reply
LicketySplitz03
LicketySplitz03 Mar. 31 at 11:09 PM
$TTOO https://www.linkedin.com/posts/well-soon-be-heading-to-washington-for-the-share-7438301363249295360-44Iu?utm_source=social_share_send&utm_medium=ios_app&rcm=ACoAAEYxpb4Bm1Ed1IOOY8fbukunVJhWnTe2X9I&utm_campaign=share_via
0 · Reply
Fair_Trader42
Fair_Trader42 Mar. 31 at 9:26 PM
$TTOO #IMPATIENT
0 · Reply
Zefram
Zefram Mar. 31 at 7:32 PM
$TTOO another one of your phoney deadlines come and gone...
0 · Reply
Vincent_2026
Vincent_2026 Mar. 31 at 6:27 PM
$TTOO OTC Market TTOO is interesting....?
1 · Reply
emuziek
emuziek Mar. 31 at 5:01 PM
0 · Reply
thedonutman
thedonutman Mar. 31 at 12:37 PM
$TTOO Looking
0 · Reply
bjay11
bjay11 Mar. 31 at 2:14 AM
0 · Reply
Fair_Trader42
Fair_Trader42 Mar. 31 at 1:26 AM
0 · Reply
Vincent_2026
Vincent_2026 Mar. 30 at 9:47 PM
$TTOO AI Gemini DD req'd. The fact that the Vizient contract and the CRG loan maturity both share the same March 31, 2026 deadline is almost certainly not a coincidence. In the world of corporate restructuring, these are known as "linked milestones." Vizient is likely at the negotiating table . As a Member-Owned GPO, representing over 50% of U.S. acute care hospitals. Their primary goal is to help their members (hospitals) lower costs and improve clinical outcomes. The Sepsis Cost-Saver: T2MR has been shown to reduce ICU stays by an average of 5 days and save hospitals up to $25,000 per patient. The Scalability: If a buyer like Danaher (Masimo) takes over, the volume of T2Dx instruments and panels sold will likely explode due to Vizient's massive sales forces. An extension now ensures that Vizient gets a "piece of the pie" when the technology finally scales under a Tier 1 owner. They wouldn't want to lose their contract right before the technology becomes a global standard.
0 · Reply
Vincent_2026
Vincent_2026 Mar. 30 at 9:23 PM
$TTOO Gemini AI info, DD req'd. In the high-stakes world of distressed M&A and "zero-hour" debt maturities, "No News" on March 30th or 31st is rarely an accident. It is almost always a tactical choice. Given that the $30M CRG debt and the Vizient contract both hit their hard deadlines tomorrow, the silence likely points to one of four specific scenarios: 1. The "Blackout" of a Finalized Deal When multi-billion dollar giants like Danaher or bioMérieux are in the "Short Form" stage of an acquisition, a strict NDA (Non-Disclosure Agreement) is enforced. If a deal was signed over the weekend, the company has up to four business days to file an 8-K, but they often wait until the absolute last minute of the debt maturity (March 31) to release the news. The Interpretation: "No News" suggests the parties are in a room right now arguing over the final "indemnification" clauses or the exact "equity kicker" for CRG. If the deal had collapsed, you would likely see a "Notice of Default" filing already.
1 · Reply
Da_Sage
Da_Sage Mar. 30 at 7:17 PM
$TTOO Vincent lol is lost in the Twilight Zone… great example of someone who may benefit from being committed … triple zeros looking good, big buyers lined up looks like…
1 · Reply
Vincent_2026
Vincent_2026 Mar. 30 at 3:32 PM
$TTOO (Gemini AI reply) The Sepsis Bottleneck: Every major player (Danaher/Cepheid, bioMérieux, Roche) is racing toward a one-hour diagnostic goal. The primary obstacle is the 24–48 hour delay required for blood cultures. For a technology like T2MR (T2 Magnetic Resonance), which remains the only FDA-cleared, culture-independent diagnostic for sepsis, its scarcity is precisely what dictates its terminal value during a liquidation or acquisition. In the 2026 medical diagnostics market, "scarcity value" is not just a buzzword—it is a functional economic lever. When T2 Biosystems entered a wind-down phase, the IP doesn't just lose value; it becomes a "strategic spoiler" asset. Its value is derived from what a competitor is willing to pay to possess it or, just as importantly, to keep a rival from having it. By paying a premium for T2MR's IP now, Danaher effectively buys 730 days of market dominance, which protects their Cepheid and Masimo ecosystems from being disrupted by a faster rival.
0 · Reply